ArticleCureus2026
A Comparative Analysis of Carboplatin- and Cisplatin-Based Concurrent Chemoradiation for Treating Locally Advanced Cervical Cancer: A Single-Center Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor locally advanced cervical cancer (LACC), cisplatin-based chemoradiotherapy (CIS + RT) is the recommended treatment; however, its toxicity profile often limits clinical application. Thus, this study evaluated treatment outcomes and toxicity of carboplatin-based chemoradiotherapy (CARBO + RT) vs. CIS + RT.
methodsThis single-center observational study included patients with LACC (Federation Internationale de Gynecologie et d'Obstetrique stages IIA-IVA) treated with weekly CARBO (area under curve 2, calculated using the Calvert formula) or CIS (40 mg/m² intravenous weekly) concurrently with standard two-dimensional external beam radiotherapy (45 Gy in 25 fractions) with subsequent intracavitary brachytherapy (7 Gy per fraction for three insertions). A total of 146 patients were analyzed (CARBO + RT: n = 72 and CIS + RT: n = 74). Primary outcome measures were tumor response rate, overall survival (OS), and two-year progression-free survival (PFS). The secondary outcome measure was acute adverse events (AEs).
resultsCARBO + RT and CIS + RT groups had comparable complete response (58.3% (n = 42) vs. 64.8% (n = 48); p = 0.692); however, treatment completion was significantly higher with CARBO + RT (94.4% (n = 68)) vs. CIS + RT (81.1% (n = 60); p = 0.014). CARBO + RT group had a higher hazard of OS (hazard ratio (HR): 1.06; 95% CI: 0.41-2.75; p = 0.901) and PFS (HR: 1.47; 95% CI: 0.70-3.072; p = 0.305), though the groups did not differ significantly. CARBO + RT was associated with significantly less vomiting (p = 0.005), while grade II-IV hematologic and nonhematologic AEs were comparable (p > 0.05).
conclusionCARBO + RT achieved oncologic outcomes comparable to CIS + RT, with superior treatment completion rates and favorable gastrointestinal tolerability. CARBO + RT represents a viable alternative, particularly in settings where CIS toxicity or hydration requirements pose clinical challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.